49 results on '"Chinn, Leslie"'
Search Results
2. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
3. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
4. Simulation‐based evaluation of personalized dosing approaches for anti‐FGFR/KLB bispecific antibody fazpilodemab.
5. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms
6. Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
7. Correction to: Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
8. Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
9. Itolizumab, a Novel Targeted Anti-CD6 Therapy, Induces Cleavage of Cell Surface CD6 and Rapid Onset of Efficacy in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease
10. Updated Interim Results from the Equate Study: Preliminary Safety and Efficacy of Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease
11. Genome-Wide Association Study Implicates PARD3B-Based AIDS Restriction
12. Genetic Associations of Variants in Genes Encoding HIV-Dependency Factors Required for HIV-1 Infection
13. Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease
14. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
15. An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities
16. Pharmacodynamic Effects of Xenobiotic ABC Transporters in Peripheral Tissues
17. Response to “Predictable difficulty or difficulty to predict”
18. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial
19. Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study
20. Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
21. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein
22. A nonpeptide provides insight into mechanisms that regulate Drosophila melanogaster heart contractions
23. 371 - Itolizumab, a Novel Targeted Anti-CD6 Therapy, Induces Cleavage of Cell Surface CD6 and Rapid Onset of Efficacy in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease
24. 372 - Updated Interim Results from the Equate Study: Preliminary Safety and Efficacy of Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease
25. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
26. Absence of Pharmacokinetic Interactions between the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate
27. FRI0129 THE BTK INHIBITOR, FENEBRUTINIB, EFFECTIVELY MODULATES B AND MYELOID CELL BIOLOGY IN RHEUMATOID ARTHRITIS PATIENTS
28. Fenebrutinib in H1antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
29. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound
30. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria
31. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
32. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
33. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound
34. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria
35. Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains
36. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
37. CRT-115 Demographics Of Study Participants In Clinical Trials For Cardiovascular Drugs Approved By FDA From 2010 To 2011
38. An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities
39. Very important pharmacogene summary
40. Response to “Predictable difficulty or difficulty to predict”
41. Genetic Variants in Nuclear-Encoded Mitochondrial Genes Influence AIDS Progression
42. Genetic Polymorphisms in ABC Transporters
43. The Human Multidrug Resistance Protein 4 (MRP4,ABCC4): Functional Analysis of a Highly Polymorphic Gene
44. Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms
45. The Effects of ABCB1 3′-Untranslated Region Variants on mRNA Stability
46. PharmGKB Submission Update: IV. PMT Submissions of Genetic Variations in ATP-Binding Cassette Transporters to the PharmGKB Network
47. Evolutionary Conservation of Vertebrate Blood-Brain Barrier Chemoprotective Mechanisms in Drosophila.
48. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.
49. The Effects of ABCB1 3'-Untranslated Region Variants on mRNA Stability
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.